BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

NewsGuard 100/100 Score
Apr 22 2011

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, England.

The data related to BCX4208 will be presented during a poster session scheduled for Thursday, May 26, 2011 from 8:00-3:30 p.m. GMT. The two posters to be presented during the session include:

  • Presentation Number THR0027: "BCX4208, A Novel Urate-Lowering Therapy, was Generally Safe and Well-Tolerated in Two 3-Week Studies in Gout Subjects"
  • Presentation Number THU0011: "BCX4208 Shows Synergistic Reductions in Serum Uric Acid (sUA) in Gout Patients when Combined with Allopurinol"

Source: http://www.biocryst.com/

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Lancet Commission predicts sharp increase in global prostate cancer cases
New molecule is one step closer to becoming a treatment for Phelan-McDermid syndrome
Recycled food waste may be contaminated with pharmaceutical residues, research reveals
Gout not just for Victorians: 1 in 40 Brits have this extremely painful disease
Gene therapy could prolong survival in some people with arrhythmogenic right ventricular cardiomyopathy
Supply chain assessment and management, optimizing pharmaceutical supply chains
Common HIV drugs linked to reduced Alzheimer's disease risk
What natural compounds can help you manage your rosacea?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status